Scarica l'app Stockscreener
92.36
3.21%
-3.06
Dopo l'orario di chiusura:
92.01
-0.35
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$95.42
Aprire:
$96.91
Volume 24 ore:
895.52K
Relative Volume:
1.14
Capitalizzazione di mercato:
$5.89B
Reddito:
$46.02M
Utile/perdita netta:
$-130.15M
Rapporto P/E:
-45.21
EPS:
-2.0427
Flusso di cassa netto:
$56.08M
1 W Prestazione:
+0.29%
1M Prestazione:
+13.34%
6M Prestazione:
+56.91%
1 anno Prestazione:
+68.23%
Intervallo 1D:
$90.92
$98.30
Intervallo di 1 settimana:
$90.92
$98.32
Portata 52W:
$39.60
$98.32
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
92.36 | 5.89B | 46.02M | -130.15M | 56.08M | -2.0427 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD - Investing.com Nigeria
Atika Capital Management LLC Takes $5.51 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
Wall Street Recap: Is Protagonist Therapeutics Inc trading at a discount2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
PTGX: Two late-stage oral peptide drugs near approval, with strong pipeline and financial flexibility - TradingView
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Responsive Playbooks and the PTGX Inflection - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD By Investing.com - Investing.com UK
Nasdaq Moves: Can Protagonist Therapeutics Inc expand into new markets2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)? - Sahm
Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - The Fayetteville Observer
Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX: Oral IL-23 and rusfertide near launches, with strong data and major market potential ahead - TradingView
TD Cowen Health Care Conference - marketscreener.com
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA Filing And Takeda Deal ShiftWhat's Changed - simplywall.st
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Benzinga
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals By Investing.com - Investing.com Canada
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):